Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Presentation will highlight opportunity for oral difelikefalin to address a significant unmet need in the treatment of pruritus in patients with NP

STAMFORD, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual event focused on notalgia paresthetica (NP) on Tuesday, September 20, 2022, from 11:00 a.m. to 12:15 p.m. ET. The presentation will highlight new data from the KOMFORT Phase 2 clinical trial of oral difelikefalin in NP, as well as feature two prominent key opinion leaders who will discuss the scientific rationale for oral difelikefalin in NP and the significant unmet clinical need. An interactive Q&A session will follow the presentation.

Presenters will include:

  • Christopher Posner, Chief Executive Officer, Cara Therapeutics
  • Eric Vandal, Senior Vice President, Commercial, Cara Therapeutics
  • Joana Goncalves, MD, Chief Medical Officer, Cara Therapeutics
  • Brian Kim, MD, MTR, Icahn School of Medicine at Mount Sinai, NY
  • Zoe Diana Draelos, MD, Dermatology Consulting Services, PLLC

A live audio webcast of the presentation and accompanying slides will be accessible under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. A replay of the webcast will be archived on the Company’s website following the presentation.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed the placebo-controlled phase of a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com

Staff

Recent Posts

cbdMD Expands Oasis Social Tonics to Total Wine

Charlotte, North Carolina--(Newsfile Corp. - June 24, 2025) - cbdMD, Inc. (NYSE American: YCBD), a…

32 minutes ago

MedsEngine Helps Medical Practices Unlock $30,000 Per Provider in Additional Annual Revenue

DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine, a leader in chronic disease management software, announced today that medical practices…

1 hour ago

Trially AI Taps Serial Entrepreneur Christian Smith as CRO to Expand AI Clinical Trial Enrollment Across U.S.

KANSAS CITY, Mo.--(BUSINESS WIRE)--#AIinHealthcare--Trially®, a breakthrough AI clinical trial recruitment technology to unlock faster qualified…

1 hour ago

cultivate(MD) Announces Portfolio Company, Virtual Incision Corporation, Appoints Jim Alecxih as Chief Executive Officer

GRAND RAPIDS, Mich., June 24, 2025 /PRNewswire/ -- cultivate(MD), a leading medical device venture capital company, is…

2 hours ago

Brainomix and 3DR Labs Partner to Advance Stroke Care in the US Through Clinically Validated AI Imaging Solution

OXFORD, England and CHICAGO, Ill., June 24, 2025 /PRNewswire/ -- Today, Brainomix, a pioneer in…

2 hours ago

Cosmo to Unveil First-of-its-Kind Clinical Study on the Use of GI Genius(TM) with Apple Vision Pro at Rush University Medical Center

Dublin, Ireland--(Newsfile Corp. - June 24, 2025) - Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that…

6 hours ago